Evidence map›Paper›PMID 40498363›Full record

SynthesisCancer metastasis reviews2025

Opioid use and the risk of cancer incidence and mortality: a systematic review.

Shakti Shrestha, Holly Foot, Mahdi Sheikh, Marie-Odile Parat, Adam La Caze

Abstract readSystematic Review
In one paragraph

Synthesis in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shakti Shrestha *School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Dutton Park, QLD, 4102, Australia.ORCID 0000-0003-0344-091X
Holly Foot *School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Dutton Park, QLD, 4102, Australia.ORCID 0000-0002-5993-9050
Mahdi SheikhGenomic Epidemiology Branch, International Agency for Research On Cancer (IARC-WHO), Lyon, France.ORCID 0000-0003-3972-7824
Marie-Odile ParatSchool of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Dutton Park, QLD, 4102, Australia. m.parat@uq.edu.au.ORCID 0000-0003-4895-7381
Adam La CazeSchool of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Dutton Park, QLD, 4102, Australia. a.lacaze@uq.edu.au.ORCID 0000-0001-6802-6141

Funding

The Opioid Cohort Consortium (OPICO) to investigate the effects of using opioids on cancer riskU01CA289226 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI Mahdi SHEIKH · 2024 to 2026
$1.7M
French National Cancer Institute INCa 2022-037NCI NIH HHS U01 CA289226NIH NCI U01CA289226World Health Organization 001
6 · The paper itself

Abstract

There is abundant but discrepant scientific literature reporting an effect of opioids on the course of cancer. The International Agency for Research on Cancer monographs recently classified opium consumption as carcinogenic to humans in certain organs, raising concerns this may be due at least in part to the alkaloids opium contains (such as morphine and codeine). This systematic review investigated whether opioid exposure among cancer-free individuals is independently associated with the risk of future cancer incidence or cancer mortality. An electronic database search was conducted in PubMed, EMBASE, Web of Science, PsycINFO, International Pharmaceutical Abstracts, CINAHL and Scopus. Studies were included if they provided a statistical estimate of cancer mortality, cancer incidence, or cancer risk following opioid exposure. Study quality was assessed using the Newcastle-Ottawa Scale. Study characteristics and outcomes were extracted and analysed in a descriptive narrative synthesis. There were 27 studies that met the inclusion criteria, representing a total of 4,542,745 participants. Twelve of the 27 were rated as high quality according to the Newcastle-Ottawa Scale. The observed data is consistent with a small increase in the risk of cancer incidence or cancer mortality following opioid exposure, particularly in a subset of organs. There is, however, considerable uncertainty in the evidence given the substantial risk of bias in estimating the overall effect of opioid exposure on cancer outcomes in these studies. This review synthesises studies reporting cancer risk following opioid exposure and identifies the key methodological factors influencing ongoing uncertainty estimating the true effect. Rigorous epidemiological studies employing specific methods to minimize bias are warranted.

Indexed as

Analgesics, OpioidNeoplasmsHumansIncidenceRisk FactorsAnalgesics, OpioidCancer incidenceCancer mortalityCancer riskOpioid exposure

Identifiers

PMID40498363
PMCPMC12159095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.